Ad
ACAD - ACADIA Pharmaceuticals Stock Trading
About | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
None
Quote | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
| Last: | $22.29 |
|---|---|
| Change Percent: | -0.18% |
| Open: | $22.16 |
| Close: | $22.29 |
| High: | $22.29 |
| Low: | $21.87 |
| Volume: | 942,972 |
| Last Trade Date Time: | 11/28/2023 03:00:00 am |
News | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
-
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United State...
-
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transit...
Message Board Posts | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $ACAD News Article - Acadia Pharmaceuticals Announces DAYBUE(TM) (trofinetide) is Now A | whytestocks | investorshangout | 04/17/2023 2:40:49 PM |
| Is Martin Shkreli in charge of Acadia, or | Doktornolittle | investorshub | 04/09/2023 12:01:33 PM |
| 30s coming folks, patience | harry crumb | investorshub | 03/13/2023 10:57:16 PM |
| $ACAD hopefully Opening will give a boost but | MiamiGent | investorshub | 03/13/2023 1:02:22 PM |
| If the price is right, yes | harry crumb | investorshub | 03/13/2023 11:34:59 AM |
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
Ad
-
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United State...
-
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transit...
-
2023-11-19 08:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...